CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...
Sizable investments. High-profile appearances at industry events. Unique development platforms. These elements would augur well for companies of any kind—and companies hoping to bring epigenome ...
Editas Medicine (NASDAQ:EDIT) is one of the best gene-editing stocks to buy according to hedge funds. On November 10, 2025, Clear Street raised its price target on Editas Medicine (NASDAQ:EDIT) to ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Editas Medicine reported promising initial results from the EDIT-301 trials for inherited blood disorders, leading to a rating upgrade to "outperform" by Raymond James. The company's financial ...
CRISPR Therapeutics CRSP reported third-quarter results in line with our expectations, and its pipeline candidates are continuing to make progress. We maintain our positive outlook and fair value ...
“Editas Medicine is making significant progress towards the clinic with our in vivo medicines in preclinical development for people living with serious diseases,” said Linda C. Burkly, Ph.D., ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
CRISPR Therapeutics CRSP reported second-quarter results in line with our expectations, and its pipeline candidates are continuing to make progress. Collaboration revenue totaled $70 million, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results